Troy Ignelzi has served as an independent director of Abivax since July 2023. He has been Chief Financial Officer of Rapport Therapeutics since October 2023 and was previously Chief Financial Officer of Karuna Therapeutics from March 2019 until its sale to Bristol Myers Squibb, and CFO of scPharmaceuticals from 2016 to 2019. Earlier he held CFO and business-development leadership roles at Juventas Therapeutics, Pharmalex, Esperion Therapeutics and Insys Therapeutics, and began his career at Eli Lilly. He currently serves on the board of Contineum Therapeutics. He holds a B.S. in accounting from Ferris State University. He chairs the Audit Committee and is a member of the Remuneration Committee.